Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $19,593.86 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CFO Austin Aerts sold 2,431 shares of Sera Prognostics stock in a transaction on Friday, January 10th. The shares were sold at an average price of $8.06, for a total value of $19,593.86. Following the completion of the sale, the chief financial officer now directly owns 283,325 shares of the company's stock, valued at $2,283,599.50. This trade represents a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Austin Aerts also recently made the following trade(s):

• On Monday, November 11th, Austin Aerts sold 7,179 shares of Sera Prognostics stock. The shares were sold at an average price of $7.32, for a total value of $52,550.28.

Sera Prognostics Stock Performance

NASDAQ:SERA traded up $0.04 on Tuesday, hitting $6.37. 134,610 shares of the stock were exchanged, compared to its average volume of 143,614. The stock has a market capitalization of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a 52 week low of $4.98 and a 52 week high of $12.35. The company's 50-day moving average price is $7.44 and its 200 day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the business posted ($0.23) earnings per share. As a group, equities research analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Barclays PLC increased its holdings in Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company's stock valued at $308,000 after purchasing an additional 30,093 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Sera Prognostics by 100.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company's stock worth $892,000 after buying an additional 75,441 shares during the period. Geode Capital Management LLC increased its stake in shares of Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company's stock valued at $4,578,000 after acquiring an additional 47,969 shares during the last quarter. Quest Partners LLC raised its position in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company's stock valued at $50,000 after acquiring an additional 5,415 shares during the period. Finally, State Street Corp boosted its stake in Sera Prognostics by 8.8% during the 3rd quarter. State Street Corp now owns 425,093 shares of the company's stock worth $3,316,000 after acquiring an additional 34,479 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.